Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety, tolerability, and immunogenicity of V114 followed by PNEUMOVAX23 in adults 50+ completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• PNEUMOVAX23 (pneumococcal polysaccharide vaccine)
• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2021-01-06